Results 171 to 180 of about 4,836 (184)

Risankizumab Versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

New England Journal of Medicine, 2017
Jean-Philippe Lacour, Howard Sofen, Melinda Gooderham   +2 more
exaly  

Risankizumab

2020
Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds, Jashin J. Wu   +3 more
openaire   +1 more source

Induction Therapy With the Selective Interleukin-23 Inhibitor Risankizumab in Patients With Moderate-to-Severe Crohn's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study

Lancet, The, 2017
Kyung-Jo Kim, Edouard Louis, Julian Panes   +2 more
exaly  

Efficacy and Safety of Risankizumab in Japanese Patients With Moderate to Severe Plaque Psoriasis: Results From the SustaIMM Phase 2/3 Trial

Journal of Dermatology, 2019
Mamitaro Ohtsuki, Hideki Fujita, Atsuyuki Igarashi   +2 more
exaly  

Risankizumab/tacrolimus

Reactions Weekly, 2021
openaire   +1 more source

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

New England Journal of Medicine
Sofie Berg, W Rachel Duan, Kristina Kligys   +2 more
exaly  

Long-Term Outcome of Risankizumab in Crohn’s Disease: A Real-World GETAID Study

Clinical Gastroenterology and Hepatology
Cyrielle Gilletta de Saint Joseph, Vered Abitbol, Sophie Geyl   +2 more
exaly  

Long-Term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology
David T Rubin, Zachary Fine, Evan Fear
exaly  

Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Journal of Crohn's and Colitis
David T Rubin, Remo Panaccione, Marc Ferrante   +2 more
exaly  

Infliximab/Risankizumab

Reactions Weekly
openaire   +2 more sources